We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Generic firms reported mixed results in the quarter ending June 30, as generic competition and research and development (R&D) expenses cut into some companies’ bottom lines. Firms releasing financial statements recently included: